Search company, investor...

DiaKine Therapeutics


Acquired | Acquired

About DiaKine Therapeutics

DiaKine Therapeutics, Inc. is a development-stage company commercializing immune modulators such as Lisofylline (LSF) and related oral compounds into therapies for diabetes and related complications. These drugs have the potential to stop the progression of diabetes and reverse damage already caused by the disease. In February 2012, DiaKine Therapeutics was acquired by Islet Sciences. The valuation of DiaKine Therapeutics was undisclosed. Other terms of the deal were not released.

Headquarters Location

1414 Sachem Place Suite 3

Charlottesville, Virginia, 22901,

United States

Missing: DiaKine Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: DiaKine Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing DiaKine Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DiaKine Therapeutics is included in 1 Expert Collection, including Diabetes.



1,902 items

DiaKine Therapeutics Patents

DiaKine Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics



Diabetes, Monoclonal antibodies, Autoimmune diseases, Experimental cancer drugs, Indoles


Application Date


Grant Date


Related Topics

Diabetes, Monoclonal antibodies, Autoimmune diseases, Experimental cancer drugs, Indoles



Latest DiaKine Therapeutics News

DiaKine secures funding in quest to stop, reverse damage of diabetes

Apr 11, 2012

Share / Apr 10, 2012 at 2:42 PM A clinical-stage company trying to reverse the damage and stop the progression of diabetes is getting a boost from $1.2 million in grants and a matching round of private funding. DiaKine Therapeutics Inc.’s lead product, Lisofylline , is a synthetic small molecule compound intended to directly enhance the insulin-producing function of islet cells and block the destruction of islet cells by inflammatory agents called cytokines. Preclinical studies have led the company to believe that its compound has the potential to stop the progression of type 1 diabetes without the use of toxic immunosuppressive drug and to reverse damage it’s already caused. The company began a phase 1 clinical trial of Lisofylline in 2009. A call to the company seeking comment on the trial’s progress was not returned. DiaKine has just received $2.1 million in grants from the National Institutes of Health and the Iacocca Foundation, and is also raising a $2.1 million round of capital , according to a recent U.S. Securities and Exchange Commission filing. So far, 17 investors have participated, according to the filing. Advertisement Therapeutics for type 1 diabetes comprise a $2.7 billion market that’s forecast to grow 6 percent annually for the next five years, according to Global Data. Monitoring diet and blood sugar, and taking insulin is still the standard of treatment, but a variety of others are under development. A vaccine being developed at the Massachusetts General Hospital is in phase 2 clinical trials , and Genzyme and Osiris’ stem cell therapy has shown promise in clinical trials. Another company, ViaCyte, is looking to start clinical trials next year for its therapy, which involves slipping an envelope filled with pancreatic cells under the skin. In March, DiaKine was acquired by New York-based Islet Sciences Inc. , a developer of technologies in the field of transplantation therapy for patients with diabetes. DiaKine says its pipeline of drugs to address type 1 diabetes, type 2 diabetes and latent autoimmune diabetes in adults targets a total addressable market of $13 billion. Topics

DiaKine Therapeutics Frequently Asked Questions (FAQ)

  • Where is DiaKine Therapeutics's headquarters?

    DiaKine Therapeutics's headquarters is located at 1414 Sachem Place, Charlottesville.

  • What is DiaKine Therapeutics's latest funding round?

    DiaKine Therapeutics's latest funding round is Acquired.

  • Who are the investors of DiaKine Therapeutics?

    Investors of DiaKine Therapeutics include Islet Sciences, AdPharma, BlueTree Allied Angels and Tall Oaks Capital.

  • Who are DiaKine Therapeutics's competitors?

    Competitors of DiaKine Therapeutics include Intarcia Therapeutics, Neuronascent, Nuon Therapeutics, Calixa Therapeutics, Palkion and 13 more.

Compare DiaKine Therapeutics to Competitors

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Diasome Pharmaceuticals

Diasome Pharmaceuticals develops hepatocyte directed vesicle technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. The company was founded in 2004 and is based in Cleveland, Ohio.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Tolera Therapeutics

Tolera Therapeutics is developing targeted therapies for immune suppression and immune tolerance, designed for use in organ transplant surgeries and other medical settings requiring safer, more targeted immune modulation. The goal is to provide improved induction therapy with a better safety profile than current treatment options. The company's technology, which stems from organ transplant research done at the Cleveland Clinic, has been undergoing clinical research and has been tested in humans. The regulatory pathway is expected to bring a product to market in 2012.

Altheus Therapeutics

Altheus Therapeutics is developing Zoenasa Oral Controlled Release and Rectal Gel formulations as front-line therapies for the treatment of inflammatory bowel disease (IBD) with the initial focus on ulcerative colitis (UC). Zoenasa is a fixed-dose combination of the anti-inflammatory mesalamine (5-aminosalicylic acid; 5-ASA) plus an antioxidant to reduce bowel injury associated with IBD. Zoenasa is formulated as a rectal gel enema to improve efficacy in patients suffering from left-sided (distal) ulcerative colitis; and as oral formulations with an extended- and delayed-release profile for patients with proximal or extensive colitis.

Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.